Jane Street’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Jane Street’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-36,000	Closed	-$591K	–	11033
2021 Q2	$591K	Sell	36,000 -34,000	-49%	-$687K	﹤0.01%	6932
2021 Q1	$1.55M	Buy	70,000 +43,400	+163%	+$1.18M	﹤0.01%	4524
2020 Q4	$823K	Buy	+26,600	New	+$673K	﹤0.01%	4989

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jane Street's TCRR Position: Q1 2023 in Review

Jane Street sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2023, closing a stake of 41,295 shares — an estimated $41.2K sold.

Jane Street first reported a position in TCRR in Q4 2020 and held it in 7 quarters. The position peaked at $1.04M in Q1 2021. 59 funds tracked by Wall St. Rank hold TCRR as of Q1 2023.

Jane Street reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jane Street sold 41,295 TCR2 Therapeutics Inc. Common Stock shares in Q1 2023, an estimated $41.2K.
Jane Street first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Jane Street's TCR2 Therapeutics Inc. Common Stock position peaked at $1.04M in Q1 2021.
59 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.